Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics -- Ignore unavailable to you. Want to Upgrade?

To: galt who wrote (813)	1/13/2025 3:53:37 PM
From: bobbseytwins2001	3 Recommendations Recommended By End2War sukit urslor Respond to of 1230

We listened to the podcast and were very pleased with the way PSS talked about Anktiva without mentioning it's name, and even more happy that he has already struck up a decent relationship with Kennedy, who could have something real to say about the new administration's approach to Cancer therapy. As for the L.A.Times, we have been subscribers for over 60 years, and only very recently has there been an attempt to improve the editorial content. Any change toward actual news would be appreciated by independents.

To: galt who wrote (813)	1/13/2025 4:28:28 PM
From: Fitzhughlaw	Read Replies (1) \| Respond to of 1230

From post # 809: "Based on my closer look at PSS in the podcast, I doubt I can bring myself to buy more." From post # 813: " It does not impact the investment. I don't make biotech investments based on individuals." Both of those statements cannot be true, and there's no way to harmonize them. That's why I asked for the basis of your low opinion of PSS; it's not about trying to get you to take any bait - just a query based upon logic.